Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AMPH Amphastar Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AMPH
Price (delayed)
$24.56
Market cap
$1.16B
P/E Ratio
8.41
Dividend/share
N/A
EPS
$2.92
Enterprise value
$1.63B
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active
Highlights
The stock's P/E is 90% less than its 5-year quarterly average of 83.9 and 30% less than its last 4 quarters average of 12.0
Amphastar Pharmaceuticals's equity has increased by 12% YoY and by 2.6% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 7% QoQ
The net income has contracted by 11% from the previous quarter and by 8% YoY
The EPS has contracted by 11% from the previous quarter and by 9% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Key stats
What are the main financial stats of AMPH
Market
Valuations
Earnings
Shares outstanding
47.14M
Market cap
$1.16B
Enterprise value
$1.63B
Price to earnings (P/E)
8.41
Price to book (P/B)
1.56
Price to sales (P/S)
1.6
EV/EBIT
8.11
EV/EBITDA
6.13
EV/Sales
2.23
Revenue
$730.66M
Gross profit
$369.01M
Operating income
$194.7M
Net income
$141.63M
EBIT
$200.77M
EBITDA
$265.38M
Free cash flow
$150.23M
Per share
Balance sheet
Liquidity
EPS
$2.92
EPS diluted
$2.76
Free cash flow per share
$3.15
Book value per share
$15.77
Revenue per share
$15.34
TBVPS
$21.87
Total assets
$1.63B
Total liabilities
$874.99M
Debt
$652.53M
Equity
$751.28M
Working capital
$388.91M
Debt to equity
0.87
Current ratio
2.95
Quick ratio
1.93
Net debt/EBITDA
1.77
Margins
Efficiency
Dividend
EBITDA margin
36.3%
Gross margin
50.5%
Net margin
19.4%
Operating margin
26.6%
Return on assets
9.1%
Return on equity
19.4%
Return on invested capital
15.9%
Return on capital employed
14.1%
Return on sales
27.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMPH stock price
How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-3.08%
1 week
-4.88%
1 month
-2.03%
1 year
-38.26%
YTD
-33.85%
QTD
-15.28%
Financial performance
How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$730.66M
Gross profit
$369.01M
Operating income
$194.7M
Net income
$141.63M
Gross margin
50.5%
Net margin
19.4%
AMPH's net margin is down by 15% year-on-year and by 11% since the previous quarter
AMPH's operating margin is down by 15% year-on-year and by 5% since the previous quarter
The net income has contracted by 11% from the previous quarter and by 8% YoY
Amphastar Pharmaceuticals's revenue has increased by 8% YoY
Price vs fundamentals
How does AMPH's price correlate with its fundamentals
Growth
What is Amphastar Pharmaceuticals's growth rate over time
Valuation
What is Amphastar Pharmaceuticals stock price valuation
P/E
8.41
P/B
1.56
P/S
1.6
EV/EBIT
8.11
EV/EBITDA
6.13
EV/Sales
2.23
The stock's P/E is 90% less than its 5-year quarterly average of 83.9 and 30% less than its last 4 quarters average of 12.0
The EPS has contracted by 11% from the previous quarter and by 9% YoY
The price to book (P/B) is 46% lower than the 5-year quarterly average of 2.9 and 40% lower than the last 4 quarters average of 2.6
Amphastar Pharmaceuticals's equity has increased by 12% YoY and by 2.6% from the previous quarter
AMPH's price to sales (P/S) is 48% less than its 5-year quarterly average of 3.1 and 38% less than its last 4 quarters average of 2.6
Amphastar Pharmaceuticals's revenue has increased by 8% YoY
Efficiency
How efficient is Amphastar Pharmaceuticals business performance
The ROIC is down by 23% year-on-year and by 12% since the previous quarter
The ROE has contracted by 22% YoY and by 13% from the previous quarter
The ROS has contracted by 15% YoY and by 8% from the previous quarter
The company's return on assets fell by 12% QoQ and by 12% YoY
Dividends
What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMPH.
Financial health
How did Amphastar Pharmaceuticals financials performed over time
The total assets is 86% greater than the total liabilities
Amphastar Pharmaceuticals's current ratio has increased by 35% YoY but it has decreased by 3.9% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 14% YoY but it has decreased by 7% QoQ
AMPH's debt is 13% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 12% YoY and by 2.6% from the previous quarter
Amphastar Pharmaceuticals's debt to equity has decreased by 6% YoY and by 2.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.